SMYD2 and acute lymphoblastic leukemia: Overexpression of SMYD2 has been reported in primary tumor samples of esophageal squamous cell carcinoma (ESCC) and pediatric acute lymphoblastic leukemia (ALL); the expression level is correlated with a poor prognosis and shortened survival of the patients [53, 54].